Aug 13, 2015 • 7:05 am EDT Corbus Pharmaceuticals Reports 2015 Second Quarter Financial Results and Provides Business Update
Aug 6, 2015 • 7:35 am EDT Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015
Jul 13, 2015 • 8:33 am EDT Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab(TM) for the Treatment of Dermatomyositis
Jun 17, 2015 • 7:05 am EDT Corbus Pharmaceuticals to Present at the JMP Securities Life Sciences Conference on June 23, 2015
Jun 12, 2015 • 8:12 am EDT Corbus Pharmaceuticals Announces FDA Orphan Drug Designation for Resunab(TM) for the Treatment of Systemic Sclerosis (Scleroderma)
Jun 5, 2015 • 8:05 am EDT Corbus Pharmaceuticals Expands Clinical Development of Resunab(TM) With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis
Jun 1, 2015 • 8:05 am EDT Corbus Pharmaceuticals Announces Presentation of Positive Data on Resunab(TM) in Pre-Clinical Models of Cystic Fibrosis at the 2015 Cystic Fibrosis Foundation Research Conference
May 18, 2015 • 8:30 am EDT Corbus Pharmaceuticals Receives FDA Clearance to Initiate Phase 2 Clinical Study of Resunab™ for the Treatment of Cystic Fibrosis